The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. · 2020
Read The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. by Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7152756.txt.
Introduction
Gordon and co-authors show exactly how the antiviral remdesivir blocks the copying enzyme of the MERS coronavirus, in the Journal of Biological Chemistry. No antiviral was approved for human coronaviruses when they wrote. Remdesivir mimics a building block of RNA and jams the viral polymerase that assembles new genomes.
Working with the MERS enzyme complex grown in insect cells, they found the drug's active form competes with the natural building block ATP and is taken up even more efficiently. Once built into the growing RNA chain, it halts copying three letters later, a delay that may hide it from the virus's proofreading enzyme. The mechanism helps explain the drug's strong effects in cell tests.
Catalog record
| CREATOR | Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus By Calvin J. Gordon, Egor P. Tchesnokov, Joy Y. Feng, Danielle P. Porter, Matthias Götte Published in: The Journal of Biological Chemistry DOI: 10.1074/jbc.AC120.013056 ABSTRACT Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome–coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome–CoV and Middle East respiratory syndrome (MERS–CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS–CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS–CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3′–5′ exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays. INTRODUCTION The emergence of a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2, formerly 2019-nCoV),3 initiated a global effort to identify effective treatments focusing on agents with demonstrated antiviral activity against SARS–CoV, Middle East respiratory syndrome (MERS–CoV), or related positive-sense RNA viruses. Although currently there are no approved antiviral drugs for the treatment of human coronavirus infections available, preclinical data with the nucleotide analog remdesivir (RDV) are promising, and human safety data are available (1). This compound shows a broad spectrum of antiviral activities against several RNA viruses (2, 3, 4), including SARS–CoV and MERS–CoV (5). RDV was originally developed for the treatment of Ebola virus disease (2). Cell-culture and animal studies revealed potent antiviral activities against filoviruses, including the Ebola virus (EBOV) (4). Subsequent studies have shown that RDV is also active against coronaviruses with divergent RNA-dependent RNA polymerases (RdRps) (5, 6). However, biochemical data that support these findings and provide a possible mechanism of action are not available. The triphosphate form of RDV (RDV-TP) was shown to inhibit the RdRp of respiratory syncytial virus (4), Nipah virus, and EBOV (7, 8), which are all nonsegmented negative-sense RNA viruses. Active Ebola RdRp contains the viral L protein in complex with viral protein 35 (9, 10). Viral protein 35 is the functional counterpart of the P protein of respiratory syncytial virus and Nipah (7, 11, 12). Previously, we generated recombinant Ebola RdRp for the study of nucleotide analog inhibitors (8). Enzyme kinetics show that RDV-TP is able to compete with its natural counterpart ATP for incorporation. The selectivity of ATP over the inhibitor is ∼4-fold. Once incorporated at position i, the compound causes inhibition of RNA synthesis predominantly at position i + 5. Delayed chain termination is therefore a plausible mechanism of action. Progress has also been made in characterizing the SARS–CoV RdRp complex (13, 14, 15). Biochemical data suggest that the active complex is composed of at least three viral nonstructural proteins nsp7, nsp8, and nsp12. The RNA polymerase nsp12 alone displays low processivity. Synthesis of longer reaction products require the additional presence of nsp7 and nsp8. Although a heterotrimer was not stable, nsp7 and nsp8 can be linked together to form a complex with nsp12 (15). Here we developed a novel expression system for the MERS–CoV RdRp complex and studied the mechanism of action of remdesivir. Co-expression of the MERS nsp5 protease with nsp7, nsp8, and nsp12 in insect cells yielded a stable complex composed of nsp8 and nsp12. We demonstrate that this complex is active on model primer/template substrates that adequately mimic the elongation state. Most importantly, selectivity measurements determined here under the inherent limitations of the steady-state conditions revealed that incorporation of the inhibitor is more efficient than its natural counterpart, and delayed chain termination is observed at position i + 3. RESULTS Expression of MERS–CoV RdRp complex The baculovirus expression system has recently been used to produce recombinant nsp12 from SARS–CoV (13). For SARS–CoV, an active RdRp complex was reconstituted with purified nsp7 and nsp8, with and without a linker, expressed in Escherichia coli (13, 15). Here, we employed an alternative approach whereby MERS nsp5, nsp7, nsp8, and nsp12 were co-expressed in insect cells as a part a polyprotein (NCBI accession no. YP_009047202.1). The polyprotein was post-translationally cleaved by the nsp5 protease at its original cleavage sites (Fig. 1 A). We also expressed a MERS–CoV RdRp complex in which the catalytic residues within the conserved motif C (SDD) of nsp12 were mutated (SNN) to generate an inactive RdRp (Fig. 1 B) (16).Figure 1Expression, purification, and characterization of the MERS RdRp complex.A, the construct contains nonstructural proteins nsp5, nsp7, nsp8, and nsp12. Red rectangles indicate original nsp5 protease cleavage sites. His8 and Strep indicate the locations of histidine and strep tags, respectively. B, a snapshot of a sequence alignment (T-Coffee) of representative RdRp enzymes from positive-sense RNA genome viruses illustrating sequence conservation within RdRp motif C. C, SDS-PAGE migration pattern of the purified enzyme preparations stained with Coomassie Brilliant Blue G-250 dye. Proteins migrating at ∼100 and ∼25 kDa contain nsp12 and nsp8, respectively. D, RNA synthesis on a short model primer/template substrate. Template and primer were both phosphorylated (p) at their 5′-ends. G indicates incorporation of the radiolabeled nucleotide opposite template position 5. RNA synthesis was monitored with the purified MERS RdRp complex wt (motif C = SDD) and active-site mutant (motif C = SNN) in the presence of NTP combinations designed to generate specific products. Lanes m illustrate the migration pattern of the radiolabeled 4-nucleotide-long primer. HCV, hepatitis C virus; NoV, norovirus; PoV, poliovirus. Nickel–nitrilotriacetic acid affinity chromatography via the N-terminal eight-histidine tag of the nsp8 protein resulted in a MERS–CoV RdRp complex containing nsp8 (∼23 kDa) and nsp12 (∼110 kDa) (Fig. 1 C). Mass spectroscopy confirmed the presence of nsp8 and nsp12, whereas there was no evidence for the presence of nsp7. The WT MERS–CoV RdRp complex was tested for RNA synthesis on short model primer/template substrates mimicking a random elongation complex during RNA synthesis. We recently used the same model substrates for the study of other RdRp enzymes (Fig. 1 D) (8, 10). The 4-nt primer/14-mer templates are designed such that [α-32P]GTP is the first incorporated nucleotide, which labels the RNA products. Reactions containing the MERS–CoV RdRp complex, primer/template, and various combinations of NTPs were initiated by the addition of Mg2+ ions. In the presence [α-32P]GTP alone, the expected 5-mer product is formed. The addition of specific combinations of NTPs generated defined reaction products: [α-32P]GTP and ATP yielded a 7-mer (Fig. 1 D, left side of the gel) or a 6-mer product (Fig. 1 D, right side of the gel), depending on the template sequence. Similarly, in